Use of Mogamulizumab for Cutaneous Adult T-cell Leukemia in a Patient Living With HIV.
Cureus
; 14(11): e31701, 2022 Nov.
Article
em En
| MEDLINE
| ID: mdl-36561586
ABSTRACT
Human T-lymphotropic virus type 1 (HTLV-1) is known to cause a rare form of leukemia/lymphoma called adult T-cell leukemia/lymphoma (ATLL). Although ATLL is known to have a high co-infection rate with human immunodeficiency virus (HIV) in areas where both viruses are endemic, clinical trials, such as the phase three trial for mogamulizumab, continue to exclude patients living with HIV. We here describe the utilization and therapeutic course of mogamulizumab for ATLL in a patient living with HIV. Unfortunately, due to exclusion of patients with co-viral infections in trials, decisions regarding clinical care in these patients remain challenging with the need to rely on retrospective publications for safety and efficacy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Cureus
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos